<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009945</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP B-34</org_study_id>
    <secondary_id>SWOG-NSABP-B-34</secondary_id>
    <secondary_id>NCCTG-NSABP-B-34</secondary_id>
    <secondary_id>CDR0000068426</secondary_id>
    <nct_id>NCT00009945</nct_id>
  </id_info>
  <brief_title>Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and
      other parts of the body. It is not yet known whether clodronate is more effective alone or
      combined with chemotherapy and /or hormonal therapy in preventing metastatic breast cancer.

      PURPOSE: Randomized phase III trial to determine the effectiveness of clodronate with or
      without chemotherapy and /or hormonal therapy in preventing metastases in women who have
      stage I or stage II breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether clodronate administered alone or in addition to adjuvant chemotherapy
           and/or hormonal therapy improves disease-free survival in women with early stage breast
           cancer.

        -  Determine whether clodronate reduces the incidence of skeletal metastases and
           non-skeletal metastases in these patients.

        -  Determine whether clodronate improves overall and relapse-free survival in these
           patients.

        -  Determine whether clodronate reduces the incidence of skeletal morbidity (e.g., skeletal
           fractures, hypercalcemia, skeletal pain, need for radiotherapy, spinal cord compression)
           in these patients.

        -  Investigate the relevance of serum markers of bone turnover as a prognostic factor for
           the development of bone metastasis in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified by age (under 50 vs 50 and over), number of positive lymph nodes (0 vs 1-3 vs 4 or
      more), and hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR]
      negative vs ER and/or PR positive). Patients are randomized to one of two treatment arms.

      Patients in both arms commence treatment within 2 weeks of randomization and continue
      treatment for 3 years in the absence of bone metastasis or unacceptable toxicity. Study
      medication must be continued in the case of documented visceral or soft tissue metastasis or
      other event without skeletal metastasis.

      Patients in both arms may also receive adjuvant chemotherapy and/or tamoxifen at the
      discretion of the protocol investigator. Patients receiving hormonal therapy begin hormonal
      therapy within 3-12 weeks after the last dose of chemotherapy and continue for a minimum of 5
      years.

      Patients who have undergone a prior lumpectomy receive adjuvant whole breast radiotherapy.
      Patients who have undergone a prior mastectomy may receive radiotherapy at the investigator's
      discretion.

      Patients are followed every 6 months for 5 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 3,323 patients will be accrued for this study within 3.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival.</measure>
    <time_frame>8 years</time_frame>
    <description>Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal Metastasis Free Survival</measure>
    <time_frame>8 years</time_frame>
    <description>Time from randomization to first diagnosis of skeletal metastasis to determine the percentage of patient free of skeletal metastasis at 8 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>8 years</time_frame>
    <description>Time from randomization to any death to determine the percentage of patients alive at 8 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>8 years</time_frame>
    <description>Time from randomization to any local, regional, or distant recurrence of breast cancer to determine the percentage of patients relapse free at 8 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non-skeletal Metastasis</measure>
    <time_frame>8 years</time_frame>
    <description>Time from randomization to incidence of non-skeletal metastasis to determine the percentage of patients free from non-skeletal metastasis at 8 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3323</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Clodronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives 2 tablets once daily for 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient receives 2 tablets once daily for 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clodronate</intervention_name>
    <description>1600 mg PO daily</description>
    <arm_group_label>Arm 1: Clodronate</arm_group_label>
    <other_name>Bonefos</other_name>
    <other_name>clodronate disodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 pills PO daily</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility

          -  Patients must have undergone either a total mastectomy or a lumpectomy with either an
             axillary dissection or sentinel node biopsy. If any sentinel node is histologically
             positive by H &amp; E, or histologically suspicious on H &amp; E and confirmed positive by
             immunohistochemistry (IHC), then the patient must have a completion axillary
             dissection.

          -  The tumor must be invasive adenocarcinoma on histologic examination with clinical
             assessment T1-3, N0-1, M0.

          -  Patients must not be participating in any other clinical trials of systemic therapy
             for early-stage breast cancer. Patients may participate in the following radiation
             therapy trials:

               -  Node-positive patients may participate in the National Cancer Institute of Canada
                  Clinical Trials Group protocol MA.20, provided the requirements of the B-34
                  protocol continue to be met. (Node-negative B-34 patients may not participate in
                  MA.20.)

               -  Node-positive mastectomy patients may participate in Southwest Oncology Group
                  protocol S9927, provided the requirements of the B-34 protocol continue to be
                  met.

          -  Patients must have an analysis of both estrogen and progesterone receptors on the
             primary tumor performed prior to randomization. Tumors will be defined as ER or
             progesterone receptor (PgR) positive if: 1) the Dextran-coated charcoal or
             sucrose-density gradient method shows them to have greater than or equal to 10 fmol/mg
             cytosol protein, or 2) if using individual laboratory criteria they can be shown to be
             positive by the enzyme immunoassay method (EIA) or immunocytochemical assay. &quot;Marginal
             or borderline,&quot; results (i.e., those not definitively negative) will also be
             considered positive.

          -  At the time of randomization, the patient must have had the following within the past
             3 months: history and physical exam, a bone scan, thoracic and lumbar spine x-rays,
             and a chest x-ray. Within the past 12 months patients must have had a gynecologic exam
             (for women who have a uterus and who will be taking tamoxifen) and a bilateral
             mammogram.

          -  At the time of randomization:

               -  the postoperative absolute neutrophil count (ANC) must be greater than or equal
                  to 1500/mm3 (or less than 1500/mm3 if, in the opinion of the investigator, this
                  represents an ethnic or racial variation of normal);

               -  the postoperative platelet count must be greater than or equal to 100,000;

               -  there must be postoperative evidence of adequate hepatic function, i.e.,

               -  total bilirubin at or below the upper limit of normal (ULN) for the laboratory;
                  and

               -  alkaline phosphatase less than 2.5 x the ULN; and

               -  the serum glutamate oxaloacetate transaminase (SGOT)/ aspartate transaminase
                  (AST) less than 1.5 x the ULN;

               -  there must be postoperative evidence of adequate renal function (serum creatinine
                  within or less than the laboratory's normal range).

          -  Serum albumin and serum calcium must be within normal limits.

          -  A patient with skeletal pain is eligible for inclusion in the study if bone scan
             and/or roentgenological examination fails to disclose metastatic disease. Suspicious
             findings must be confirmed as benign by x-ray, MRI, or biopsy.

          -  Patients with prior nonbreast malignancies are eligible if they have been disease-
             free for greater than or equal to 5 years before randomization and are deemed at low
             risk for recurrence by their treating physicians. Patients with squamous or basal cell
             carcinoma of the skin that has been effectively treated, carcinoma in situ of the
             cervix that has been treated by surgery only, or lobular carcinoma in situ (LCIS) of
             the ipsilateral or contralateral breast treated by hormone therapy and/or surgery only
             are eligible, even if these were diagnosed within 5 years before randomization.

          -  Patients must have a Zubrod performance status of 0, 1, or 2.

          -  Special conditions for eligibility of lumpectomy patients: Irradiation and surgery.
             Patients treated by lumpectomy and axillary node dissection (or no axillary dissection
             if sentinel node biopsy is negative) to be followed by breast radiation therapy must
             meet all the eligibility criteria in addition to the following:

               -  Generally, lumpectomy should be reserved for tumors less than 5 cm. However, at
                  the investigator's discretion, patients treated with lumpectomy for tumors
                  greater than or equal to 5 cm are eligible.

               -  The margins of the resected specimen must be histologically free of invasive
                  tumor and ductal carcinoma in situ (DCIS). For patients in whom pathologic
                  examination demonstrates tumor present at the line of resection, additional
                  operative procedures may be performed to obtain clear margins. This is
                  permissible even if axillary dissection has been performed. Patients in whom
                  tumor is still present at the resected margins after re-excision(s) must undergo
                  total mastectomy to be eligible.

        Ineligibility.

          -  Significant non-malignant bone disease that is likely to interfere with the
             interpretation of bone x-rays.

          -  Ulceration, erythema, infiltration of the skin or the underlying chest wall (complete
             fixation), peau d'orange, or skin edema of any magnitude. (Tethering or dimpling of
             the skin or nipple inversion should not be interpreted as skin infiltration. Patients
             with these conditions are eligible.)

          -  Ipsilateral lymph nodes that on clinical examination are found to be fixed to one
             another or to other structures (cN2 disease).

          -  Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or
             infraclavicular nodes, unless there is biopsy evidence that these are not involved
             with tumor.

          -  Prior therapy for breast cancer, including irradiation, chemotherapy, biotherapy,
             and/or hormonal therapy, with the exception of tamoxifen. Tamoxifen may be given as
             adjuvant therapy before study entry, but only if it was started within 28 days before
             randomization. Patients who started tamoxifen within 28 days before randomization and
             who are being considered for chemotherapy must have their tamoxifen stopped at the
             start of chemotherapy.

          -  Prior history of breast cancer, except LCIS.

          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement
             therapy, etc. (These patients are eligible only if this therapy is discontinued prior
             to randomization.) Exceptions: patients may use low-dose estrogen vaginal creams or
             Estring® for symptomatic vaginal dryness, raloxifene (or other selective estrogen
             receptor modulators [SERMs]) for the prevention of osteoporosis, and
             luteinizing-hormone-releasing hormone (LHRH) agonists/antagonists for the purpose of
             medical ovarian ablation as a component of adjuvant therapy for the breast cancer.

          -  Patients currently taking alendronate (Fosamax®) or other bisphosphonates or
             calcitonin to treat or prevent osteoporosis are not eligible.

          -  Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude a patient from being subjected to any of the treatment options or would
             prevent prolonged follow-up.

          -  Psychiatric or addictive disorders that would preclude obtaining informed consent.

          -  Pregnancy or lactation at the time of proposed randomization. This protocol excludes
             pregnant or lactating women because the effects of clodronate on such women have not
             been studied fully.

          -  Bilateral malignancy or a mass or mammographic abnormality in the opposite breast
             suspicious for malignancy unless there is biopsy proof that the mass is not malignant.

          -  Special conditions for ineligibility of lumpectomy patients: Irradiation and surgery.
             The following patients will also be ineligible:

               -  Patients with diffuse tumors (as demonstrated on mammography) that would not be
                  considered surgically amenable to lumpectomy.

               -  Patients treated with lumpectomy in whom there is another clinically dominant
                  mass or mammographically suspicious abnormality within the ipsilateral breast
                  remnant. Such a mass must be biopsied and demonstrated to be histologically
                  benign prior to randomization or, if malignant, must be surgically removed with
                  clear margins.

               -  Patients in whom the margins of the resected specimen are involved with invasive
                  tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to
                  obtain free margins are allowed. Patients in whom tumor is still present after
                  the additional resection(s) must undergo mastectomy to be eligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Mayo Clinic Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Biloxi</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Cancer Institute</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Radiation Therapy Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004 May;62(5):527-34.</citation>
    <PMID>15122554</PMID>
  </reference>
  <results_reference>
    <citation>Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 2003;26(9):661-71.</citation>
    <PMID>12814333</PMID>
  </results_reference>
  <results_reference>
    <citation>Atula ST, Paterson AHG, Powles TJ, et al.: Safety profile of oral clodronate during long-term use in primary breast cancer patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-100, 25, 2003.</citation>
  </results_reference>
  <results_reference>
    <citation>Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002 Aug 1;20(15):3219-24.</citation>
    <PMID>12149294</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>October 17, 2017</results_first_submitted>
  <results_first_submitted_qc>October 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2017</results_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clodronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Clodronate</title>
          <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Placebo</title>
          <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1662"/>
                <participants group_id="P2" count="1661"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1655"/>
                <participants group_id="P2" count="1656"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no follow up data</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clodronate</title>
          <description>Clodronate</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1662"/>
            <count group_id="B2" value="1661"/>
            <count group_id="B3" value="3323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10.5"/>
                    <measurement group_id="B2" value="53" spread="10.4"/>
                    <measurement group_id="B3" value="54" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1662"/>
                    <measurement group_id="B2" value="1661"/>
                    <measurement group_id="B3" value="3323"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival.</title>
        <description>Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Clodronate</title>
            <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival.</title>
          <description>Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1655"/>
                <count group_id="O2" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Metastasis Free Survival</title>
        <description>Time from randomization to first diagnosis of skeletal metastasis to determine the percentage of patient free of skeletal metastasis at 8 years</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Clodronate</title>
            <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Metastasis Free Survival</title>
          <description>Time from randomization to first diagnosis of skeletal metastasis to determine the percentage of patient free of skeletal metastasis at 8 years</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1655"/>
                <count group_id="O2" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from randomization to any death to determine the percentage of patients alive at 8 years</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Clodronate</title>
            <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from randomization to any death to determine the percentage of patients alive at 8 years</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1655"/>
                <count group_id="O2" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6"/>
                    <measurement group_id="O2" value="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Free Survival</title>
        <description>Time from randomization to any local, regional, or distant recurrence of breast cancer to determine the percentage of patients relapse free at 8 years</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Clodronate</title>
            <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Free Survival</title>
          <description>Time from randomization to any local, regional, or distant recurrence of breast cancer to determine the percentage of patients relapse free at 8 years</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1655"/>
                <count group_id="O2" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9"/>
                    <measurement group_id="O2" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Non-skeletal Metastasis</title>
        <description>Time from randomization to incidence of non-skeletal metastasis to determine the percentage of patients free from non-skeletal metastasis at 8 years</description>
        <time_frame>8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Clodronate</title>
            <description>Patient receives 2 tablets once daily for 3 years.
clodronate: 1600 mg PO daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Patient receives 2 tablets once daily for 3 years.
placebo: 2 pills PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Non-skeletal Metastasis</title>
          <description>Time from randomization to incidence of non-skeletal metastasis to determine the percentage of patients free from non-skeletal metastasis at 8 years</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1655"/>
                <count group_id="O2" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                    <measurement group_id="O2" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants at Risk includes any patient who submitted an AE form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Clodronate</title>
          <description>Clodronate</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="340" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="350" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST/SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Avascular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1612"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1623"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Department of Regulatory Affairs</name_or_title>
      <organization>NSABP Foundation, Inc.</organization>
      <phone>412-339-5300</phone>
      <email>regulatory@nsabp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

